NCT06119789

Precision Cancer Therapy in Rare Cancers

The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Oslo University Hospital · Academic / Other
• Sex: All
• Age: 16 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Detailed description

All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.

Conditions

• Rare Malignant Neoplasm

Interventions

Type	Name	Description
DRUG	Imatinib	imatinib treatment based on molecular alterations
DRUG	Trametinib	According to biomarkers
DRUG	Dabrafenib	According to biomarkers

Timeline

• Start date: 2025-03-20
• Primary completion: 2033-11-30
• Completion: 2036-08-01
• First posted: 2023-11-07
• Last updated: 2025-03-26

Locations

1 site across 1 country: Norway